New York, NY, United States of America

Matthew J Scanlan



Average Co-Inventor Count = 5.6

ph-index = 8

Forward Citations = 310(Granted Patents)


Location History:

  • NY, NY (US) (2009)
  • New York, NY (US) (1996 - 2013)
  • Princeton Junction, NJ (US) (2010 - 2013)

Company Filing History:


Years Active: 1996-2013

Loading Chart...
Loading Chart...
35 patents (USPTO):Explore Patents

Title: Matthew J. Scanlan: Innovator in Cancer Research

Introduction

Matthew J. Scanlan, based in New York, NY, is a distinguished inventor with an impressive portfolio of 35 patents. His work primarily focuses on advancements in cancer research, specifically targeting therapies that utilize immunogenic proteins.

Latest Patents

Among his recent innovations, Scanlan has developed a method for inducing cell lysis using immunogenic portions of the NY-ESO-1 protein. This invention relates to peptides that can effectively bind to MHC Class I and Class II molecules, proving beneficial in various therapeutic and diagnostic applications. Another notable patent encompasses A34 and A33-like 3 DNA proteins, including antibodies and methodologies for cancer treatment. This patent illustrates the importance of detecting cancers expressing these unique polypeptides, providing a basis for diagnosing and inhibiting the effects of cancer in patients.

Career Highlights

Matthew J. Scanlan has leveraged his expertise at notable institutions such as the Ludwig Institute for Cancer Research and Memorial Sloan Kettering Cancer Center. His contributions in both environments have significantly advanced understanding and treatment approaches in oncology.

Collaborations

Throughout his career, Scanlan has collaborated with prominent researchers in the field, including Yao-Tseng Chen and Lloyd J. Old. These partnerships have fostered a collaborative spirit aimed at pushing the boundaries of cancer research and developing innovative therapies.

Conclusion

In conclusion, Matthew J. Scanlan stands out as an influential inventor whose work has the potential to transform cancer diagnosis and treatment. With his extensive patent portfolio and contributions to reputable research institutions, Scanlan continues to be a key figure in innovations that battle cancer.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…